obstructive hypertrophic cardiomyopathy
Cardiovascular · 2022–2023
3decisions
1medicine
3carried consumer input
5individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| mavacamten Treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM), specifically those with NYHA class II or III symptoms, confirmed left… | Jul 2023 | Not recommended | 5 individuals Cardiomyopathy Association |
| mavacamten Treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM) with peak left ventricular outflow tract (LVOT) gradient of at least 50 mm… | Nov 2023 | Recommended | input received |
| mavacamten Treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM). Specifically for patients with confirmed symptomatic obstructive HCM, peak… | Nov 2022 | Not recommended | input received New York Health Association |
Who spoke
Cardiomyopathy Association · New York Health Association
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.